Association between a Polymorphism in miR-34b/c and Susceptibility to Cancer - a Meta-analysis

Zhuo Lin¹, Li Chen², Mei Song¹, Ke-Qing Shi¹, Kai-Fu Tang²*

Abstract

MicroRNAs (miRNAs) act as tumor suppressors or promoters in neoplasia by regulating relative gene expression. The association between a single nucleotide polymorphism (SNP) rs4938723 in miR-34b/c and susceptibility to cancers was inconsistent in previous studies. In this study, we conducted a literature search of PubMed, Web of Science and Embase to identify all relevant studies in this meta-analysis with 6,036 cases and 6,204 controls. We found that the miR-34b/c rs4938723 polymorphism was significantly associated with increased risk of cancers in the heterozygous model (TC versus TT, OR=1.09, 95% CI=1.01-1.18, P=0.02). Subgroup analysis also revealed increased risk for Asian ethnicity in the heterozygous model (TC versus TT, OR=1.12, 95% CI=1.02-1.22, P=0.02), but decreased risk of colorectal cancer in homozygote model (CC versus TT, OR=0.66, 95% CI=0.47-0.92, P=0.02) and in the recessive model (CC versus TC+TT, OR=0.67, 95% CI=0.48-0.93, P=0.02) by cancer type. The current meta-analysis indicated that the miR-34b/c rs4938723 polymorphism may decrease susceptibility to colorectal cancer. Well-designed studies with larger sample size are required to further validate the results.

Keywords: miR - 34b/c - rs4938723 - polymorphism - cancer - meta-analysis

Introduction

MicroRNAs (miRNAs) are a class of non-coding RNA of approximately 20-24 nucleotides in length and highly evolutionarily conserved, which act the role of significant regulators in post transcription of gene expression. Emerging evidence indicates that miRNAs are related with various biological processes, such as cell proliferation, apoptosis, differentiation and metabolism, particularly in carcinogenesis that act as regulators to regulate the expression of tumor genes (Ambros, 2004; Jansson et al., 2012; Ji et al., 2014). Although the exact mechanism underlying miRNA deregulation in cancers remains unknown, some key dysregulated miRNAs have already been used as molecular biomarkers, which could improve diagnosis, prognosis, and monitoring of treatment response for cancers (Ruan et al., 2009). Single nucleotide polymorphisms (SNPs) are a kind of genetic variations associated with population diversity, disease susceptibility, drug metabolism and genome evolution (Hanchard, 2005). SNPs located in miRNA genes region could affect miRNA expression or maturation and then contribute to cancer risk (Parlayan et al., 2014). Thus, SNPs in miRNAs are ideal predictive factor for cancer risk, because they could generate significant effect in the development of cancers.

As some miRNAs appear to have their own promoters, SNPs in the promoter region may play critical roles in the development of human cancers. Recently, a potentially functional polymorphism rs4938723 (T>C) has been discovered in the promoter region of miR-34b/c. The T to C shift of the rs4938723 polymorphism was predicted to influence the GATA-X binding sites. If the polymorphic location is C, it can bind to the GATA-X transcription factors; otherwise, it cannot bind to the GATA-X transcription factors. GATA-X transcription factors can activate or repress expression of target genes when they bind to a specific DNA sequence (A/T) GATA (A/G) in the region of promoters (Bossard et al., 1998). In recent years, some case-control studies have been conducted to determine the association between rs4938723 and multiple kinds of cancers in various types, such as hepatocellular carcinoma (Xu et al., 2011; Han et al., 2013; Son et al., 2013), colorectal cancer (Gao et al., 2013; Oh et al., 2014), renal cell cancer (Zhang et al., 2014), esophageal cancer (Yin et al., 2013), nasopharyngeal carcinoma (Li et al., 2013) and breast cancer (Bensen et al., 2013). However, the results are conflicting and inconclusive. Therefore, we conducted the present meta-analysis of all relevant studies from publication to obtain a more accurate evaluation of the association between miR-34b/c rs4938723 polymorphism and cancer risk.

¹Department of Infection and Liver Diseases, Institution of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, ²Institute of Genomic Medicine, Wenzhou Medical University, Wenzhou, China  *For correspondence: tang_kafu@aliyun.com
Materials and Methods

Search Strategy and Study Selection

We conducted a comprehensive search on PubMed, Web of Science and Embase to identify all potentially eligible studies on miR-34b/c rs4938723 polymorphism and cancer risk. The search covered all papers published up to April 10, 2014, by using the following strategy: (pre-mir-34b/c OR pri-miR-34b/c OR mir-34b/c OR microRNA-34b/c OR rs4938723) and (gene OR polymorphism OR allele OR variation) and (cancer OR cancerous OR tumor OR tumour), without any restriction on language. References of the relevant articles on miR-34b/c polymorphism were also filtrated. Eligible studies should conform to all of the following criteria: 1) estimation of miR-34b/c rs2938723 polymorphism and cancer risk; 2) independent case-control studies; 3) sufficient data for estimating the odds ratio (OR) with 95% confidence interval (CI) and a P-value. If one study included two or more case-control studies by subgroup such as ethnicity, then it would be divided into two or more independent studies.

Data Extraction

Serviceable informations were extracted independently by two investigators from all eligible studies accorded with the inclusion criteria. Disagreements were reconciled through discussion between the two investigators. The following informations were extracted from each study: first author’s name, publication year, origin country, ethnicity of study population, cancer type, genotyping method, numbers of cases and controls for each genotype. Genetic equilibrium of miR-34b/c polymorphism under Hardy-Weinberg equilibrium (HWE) was evaluated by using the chi-square test for each study in controls (Wigginton et al., 2005).

Statistical Analysis

Crude OR with 95% CI was applied to evaluate the strength of the association of miR-34b/c rs4938723 polymorphism and cancer risk ( Woolf, 1955). The statistical significance of the pooled OR was detected by Z-test and p<0.05 was considered statistically significant. We investigated the association between genetic variants and cancer risk in allele model (C versus T), homozygous model (CC versus TT), heterozygous model (TC versus TT), dominant model (CC+TC versus TT) and recessive model (CC versus TC+TT), respectively. Subgroup analysis was also carried out by ethnicity and cancer type (if one ethnicity or one cancer type contained only one single study, it was merged into other subgroups).

The statistical heterogeneity between studies was detected by Q-test (Higgins et al., 2003) and a p-value of <0.05 or I2 value of ≥50% was considered to be representative of statistically significant heterogeneity, then the pooled OR was calculated by the random-effects model (DerSimonian et al., 2007). Otherwise, the fixed-effects model was used in meta-analysis (Mantel et al., 1959). Sensitivity analysis was performed to assess the stability of the results. Each study was removed in turn from the total, and the remaining studies were reanalyzed (Thakkinstian et al., 2005). Publication bias was detected by Begg’s funnel plot and Egger’s linear regression method with p<0.05 being considered statistically significant (Egger et al., 1997).

All statistical analysis was carried out using the the STATA software package version 12.0 (STATA Corp, College Station, Texas) and p<0.05 was considered statistically significant.

Results

Study Identification

In accordance with the inclusion criteria, 10 eligible studies were collected in this meta-analysis, with 6036 cases and 6204 controls. The details of the selection process were presented in Figure 1. Among the 10 studies, 8 studies were conducted in Asian population, 1 study was conducted in Caucasian population, and 1 study was conducted in African population. Various cancer types included hepatocellular carcinoma (3 studies), colorectal cancer (2 studies), breast cancer (2

Table 1. Main characteristics of studies included in the meta-analysis for miR-34b/c rs4938723

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Country</th>
<th>Ethnicity</th>
<th>Cancer type</th>
<th>Genotyping methods</th>
<th>Number of cases/controls</th>
<th>Genotypes distribution of cases</th>
<th>Genotypes distribution of controls</th>
<th>HWE(P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zhang</td>
<td>2014</td>
<td>China</td>
<td>Asian</td>
<td>RCC</td>
<td>TaqMan</td>
<td>710/760</td>
<td>302</td>
<td>324/84</td>
<td>0.12</td>
</tr>
<tr>
<td>Oh</td>
<td>2014</td>
<td>Korea</td>
<td>Asian</td>
<td>CRC</td>
<td>PCR-RFLP</td>
<td>545/428</td>
<td>272</td>
<td>233/40</td>
<td>0.40</td>
</tr>
<tr>
<td>Yin</td>
<td>2013</td>
<td>China</td>
<td>Asian</td>
<td>ESCC</td>
<td>LDR</td>
<td>600/673</td>
<td>277</td>
<td>278/45</td>
<td>0.66</td>
</tr>
<tr>
<td>Son</td>
<td>2013</td>
<td>Korea</td>
<td>Asian</td>
<td>HCC</td>
<td>PCR-RFLP</td>
<td>157/201</td>
<td>69</td>
<td>75/13</td>
<td>0.37</td>
</tr>
<tr>
<td>Li</td>
<td>2013</td>
<td>China</td>
<td>Asian</td>
<td>NPC</td>
<td>PCR-RFLP</td>
<td>217/360</td>
<td>82</td>
<td>104/31</td>
<td>0.89</td>
</tr>
<tr>
<td>Han</td>
<td>2013</td>
<td>China</td>
<td>Asian</td>
<td>HCC</td>
<td>TaqMan</td>
<td>1013/999</td>
<td>451</td>
<td>444/118</td>
<td>0.18</td>
</tr>
<tr>
<td>Gao</td>
<td>2013</td>
<td>China</td>
<td>Asian</td>
<td>CRC</td>
<td>PCR-RFLP</td>
<td>347/488</td>
<td>175</td>
<td>144/28</td>
<td>0.33</td>
</tr>
<tr>
<td>Bensen</td>
<td>2013</td>
<td>America</td>
<td>Caucasian</td>
<td>BC</td>
<td>Genotyping Array</td>
<td>1203/1088</td>
<td>496</td>
<td>563/144</td>
<td>0.69</td>
</tr>
<tr>
<td>Bensen*</td>
<td>2013</td>
<td>America</td>
<td>African</td>
<td>BC</td>
<td>Genotyping Array</td>
<td>742/658</td>
<td>362</td>
<td>317/63</td>
<td>0.32</td>
</tr>
<tr>
<td>Xu</td>
<td>2011</td>
<td>China</td>
<td>Asian</td>
<td>RCC</td>
<td>PCR-RFLP</td>
<td>502/549</td>
<td>204</td>
<td>236/62</td>
<td>0.65</td>
</tr>
</tbody>
</table>

RCC: renal cell cancer; CRC: colorectal cancer; ESCC: esophageal cancer; HCC: hepatocellular carcinoma; NPC: nasopharyngeal carcinoma; BC: breast cancer; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; LDR: ligation detection reaction; HWE: Hardy-Weinberg equilibrium; P: p value.* The study from the same article

Association between a Polymorphism in miR-34b/c and Susceptibility to Cancer

Quantitative Data Synthesis

The association of miR-34b/c rs4938723 polymorphism and cancer risk was investigated in 10 studies. And results of pooled analysis revealed that an increased risk was observed for the comparison of heterozygous model (TC versus TT, OR=1.09, 95% CI=1.01-1.18, P=0.02). In the stratified analysis by ethnicity, an association between miR-34b/c polymorphism and cancer risk was detected in Asian population for comparison of heterozygous model (TC versus TT, OR=1.09, 95% CI=1.02-1.22, P=0.02). Further subgroup analysis by cancer type

Figure 1. Flow Chart of The Study Selection Process

Table 2. Meta-analysis of miR-34b/c rs4938723 polymorphism with cancer risk

<table>
<thead>
<tr>
<th>Studies</th>
<th>N*</th>
<th>OR (95% CI)</th>
<th>P-h</th>
<th>F</th>
<th>OR (95% CI)</th>
<th>P-h</th>
<th>F</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>10</td>
<td>1.04 (0.95, 1.15)</td>
<td>0.38</td>
<td>0.002</td>
<td>65.8</td>
<td>1.00 (0.81, 1.25)</td>
<td>0.97</td>
</tr>
<tr>
<td>Cancer type</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCC</td>
<td>3</td>
<td>1.15 (0.97, 1.36)</td>
<td>0.10</td>
<td>0.11</td>
<td>54.2</td>
<td>1.15 (0.92, 1.44)</td>
<td>0.22</td>
</tr>
<tr>
<td>BC</td>
<td>2</td>
<td>0.98 (0.84, 1.15)</td>
<td>0.34</td>
<td>0.12</td>
<td>57.6</td>
<td>0.87 (0.70, 1.08)</td>
<td>0.24</td>
</tr>
<tr>
<td>CRC</td>
<td>2</td>
<td>0.87 (0.71, 1.07)</td>
<td>0.18</td>
<td>0.15</td>
<td>50.9</td>
<td>0.66 (0.47, 0.92)</td>
<td>0.02</td>
</tr>
<tr>
<td>Other</td>
<td>3</td>
<td>1.12 (0.91, 1.37)</td>
<td>0.29</td>
<td>0.03</td>
<td>72.0</td>
<td>1.21 (0.68, 2.13)</td>
<td>0.52</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asian</td>
<td>8</td>
<td>1.06 (0.94, 1.20)</td>
<td>0.32</td>
<td>0.003</td>
<td>68.2</td>
<td>1.04 (0.79, 1.37)</td>
<td>0.78</td>
</tr>
<tr>
<td>Other</td>
<td>2</td>
<td>0.98 (0.84, 1.15)</td>
<td>0.84</td>
<td>0.12</td>
<td>57.6</td>
<td>0.87 (0.70, 1.08)</td>
<td>0.21</td>
</tr>
</tbody>
</table>

*The number of studies included: RCC: renal cell cancer; CRC: colorectal cancer; ESCC: esophageal cancer; HCC: hepatocellular carcinoma; NPC: nasopharyngeal carcinoma; BC: breast cancer; OR: odds ratio; CI: confidence interval; P: p value; P-h: p value of Q for heterogeneity

Figure 2. Forest Plot of ORs for The Association of miR-34b/c rs4938723 with The Risk of Cancers in Subgroup Analysis by Cancer Type. (A) homozygote model; (B) recessive model
indicated that miR-34b/c polymorphism may decreased the risk of colorectal cancer in homozygote model (CC versus TT, OR=0.66, 95% CI=0.47-0.92, $P=0.02$) and in recessive model (CC versus TC+TT, OR=0.67, 95% CI=0.48-0.93, $P=0.02$), but no evidence of association with hepatocellular carcinoma, breast cancer, and other cancers in any genetic models (Table 2). Figure 2 gives the forest plot that provides study-specific and pooled ORs for the association of miR-34b/c polymorphism with the risk of cancers by cancer type under homozygote model and recessive model.

Sensitivity Analysis and Publication Bias

Sensitivity analysis was carried out to evaluate the influence of each individual study on pooled OR by removing each study in turn. The results indicated that the pooled OR was not changed significantly when each individual study was removed in sequence.

Begg’s funnel plot and Egger’s test were also performed to evaluate the publication bias of included studies. The results indicated that no significant publication bias was detected from the Begg’s funnel plot and Egger’s test for all the comparison models. Figure 3 gives the Begg’s funnel plot of publication bias for miR-34b/c rs4938723 polymorphism with risk of cancers.

Discussion

MiR-34b/c rs4938723 is located in promoter region of pri-miR-34b/c and may generate a GATA-X binding site by bioinformatic prediction, thus the existence of rs4938723 polymorphism may affect the expression of miR-34b/c by transcriptional mechanisms. Evidence from studies showed that miR-34b/c can arrest cell cycle in G1 phase, the abnormal expression of miR-34b/c can affect cell proliferation and colony formation (Corney et al., 2007; Hermeking, 2010).

Several studies were conducted to investigate the association between miR-34b/c rs4938723 polymorphism and risk of various cancers, including hepatocellular carcinoma, colorectal cancer, breast cancer, and other cancers. However, the results were contradictory and inconclusive. To better understanding of the association between miR-34b/c rs4938723 polymorphism and risk of cancers, a meta-analysis with larger sample and subgroup analysis is necessary. The current study is the largest meta-analysis of the association of miR-34b/c rs4938723 polymorphism with risk of cancers.

A total of 10 case-control studies were analyzed in this meta-analysis to perform a comprehensive evaluation of the association between miR-34b/c rs4938723 polymorphism and cancer risk. Our study showed that the TC genotype of rs4938723 significantly increased risk of cancers with the comparison to TT genotype when all the 10 case-control studies were merged into the meta-analysis. When stratified by ethnicity, we found the TC genotype of rs4938723 statistically significant increased risk of cancers with the comparison to TT genotype in Asian population, but not in other ethnicities. This may be due to the relatively small sample size that might affect the statistical results in other ethnicities.

In subgroup analysis by cancer type, we found significant association between miR-34b/c polymorphism and decreased risk in colorectal cancer in homozygote model and in recessive model, but not in hepatocellular carcinoma, breast cancer, and other cancers in any comparison models. This may be explained that the effect of gene polymorphism on cancer susceptibility is various to different cancer types. In addition, when all the studies were classified by cancer type, the relatively small samples in subgroup analysis might have an influence to statistical results due to insufficient statistical power.

However, some limitations should be taken into consideration in our study. First, some studies had a relatively small case-control size, and this may result in low power to statistical analysis, especially in subgroup analysis. Second, a lack of original data such as age, gender, drinking and other variables from the reviewed studies prevented an adjustment by interacting with genetic factors, could affect the evaluation of a marginal association between SNP and susceptibility to cancers. Finally, most of the patients were mainly from Asian population, this limited the application of the finding in other ethnicities from the meta-analysis.

In conclusion, this meta-analysis indicated that mir-34b/c rs4938723 polymorphism may decrease the susceptibility of colorectal cancer, but not in other cancers.
Association between a Polymorphism in miR-34b/c and Susceptibility to Cancer

Further studies with a larger sample size in different cancer types and additional ethnic groups are required to clarify the association of this polymorphism with cancer risk.

References


